Global Atopic Dermatitis (Atopic Eczema) Treatment Market Statistics, Development and Growth 2017 to 2023
Summary – A New Market Study, “Global
Atopic Dermatitis (Atopic Eczema) Treatment Market: Market Estimation,
Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast
2017 to 2023” Has Been
Featured On Wiseguyreports.
Global atopic
dermatitis treatment market is driven by increased R&D funding to develop
biologics and development of targeted therapies for atopic dermatitis. In
addition increased incidence of atopic dermatitis, new product launches, and
increased awareness about the symptoms of atopic dermatitis expected to further
boost the atopic dermatitis treatment market. However, availability of the
generic drugs and high cost of dermatology drugs are expected to hamper the
atopic dermatitis treatment market during the forecast period.
Atopic
dermatitis treatment market has been segmented on the basis of drug type, route
of administration and distribution channel
Based on drug
type, atopic dermatitis treatment market is segmented into
Corticosteroids
Calcineurin
Inhibitors
Immunosuppressants
Phosphodiesterase
type 4 (PDE-4) inhibitor
Antibiotics
Antihistamines
Emollients
Based on
route of administration, atopic dermatitis treatment market is segmented into
Oral
Topical
Parenteral
Based on
distribution channel, atopic dermatitis treatment market is segmented into
Hospital
Pharmacies
Retail
Pharmacies
Online
Pharmacies
Atopic
dermatitis treatment market expected to grow at steady state during the
forecast period. Market players are focusing on research and development to
discover new drugs to treat atopic dermatitis. Several global and regional
players competing for the market share. Companies adopting several strategies
such as acquisitions, mergers and partnering with other players to withstand
the competition and grow their market share. For instance, AstraZeneca has
entered into an agreement with LEO Pharma A/S, for the global license to
tralokinumab in skin diseases. Tralokinumab is a potential new medicine that is
being developed in phase II clinical trials for the treatment of patients with
atopic dermatitis. In December 2016, Novartis acquired UK based Ziarco Group
and expanded its R&D portfolio with once daily oral H4 receptor agonist,
ZPL389, that is being developed for the treatment of atopic dermatitis. In
addition, new classes of products are launched targeting atopic dermatitis
other than the traditional classes such as corticosteroids. This gives the
health care professionals to choose various alternatives. For instance, in
February 2017, Pfizer got FDA approval for Eucris, a non-steroidal topical
phosphodiesterase-4 inhibitor that is used for treatment of mild to moderate
atopic dermatitis.
Geographically
atopic dermatitis treatment market has been segmented into following regions
Viz. North America, Latin America, Asia-Pacific, Europe, and Middle East
&Africa. North America dominates atopic dermatitis treatment market,
expected to show notable growth rates owing to product launches, lifestyle
changes, and early treatment adoption. According to the national eczema
association in the U.S., 31.6 million people are living with eczema. Europe
atopic dermatitis treatment due to large research and development activities.
The Asia Pacific market is expected to grow at a higher rate owing to rapid
population growth, availability of large patient pool and changing lifestyle.
Some of the
market players in atopic dermatitis treatment market include Leo Pharma A/S
(Denmark), Velite Pharmaceutical (India), Nestlé S.A. (Galderma SA)
(Switzerland), Pfizer Inc. (U.S.), Anacor Pharmaceutical Inc. (U.S.), Regeneron
Pharmaceuticals, Inc. (U.S), Sanofi S.A. (France), Novartis AG (Switzerland),
Bayer AG (Germany), Mylan N.V. (Meda Pharmaceuticals) (U.S.), Bristol-Myers
Squibb (BMS) (U.S), and Allergan Plc. (Ireland) to name a few.
In March
2017, Dupixent(dupilumab), the first and only biologic medicine for the
treatment of adults with moderate-to-severe atopic dermatitis, approved by U.S.
Food and Drug Administration (FDA). This drug was developed by Sanofi and
Regeneron Pharmaceuticals in collaboration.
Report
Outline:
The report
provides granular level information about the market size, regional market
share and forecast from 2017-2023
The report
covers in-detail insights about the competitor’s overview, key findings and
their key strategies
The report
outlines drivers, restraints, challenges, and trends that are currently faced
by the industry
The report
tracks recent innovations, key developments and startup’s details that are
working in the industry
The report
provides plethora of information about market entry strategies, regulatory
framework and reimbursement scenario
For More Details : https://www.wiseguyreports.com/reports/2753873-global-atopic-dermatitis-atopic-eczema-treatment-market-market-estimation-dynamics
About Us:
Wise Guy Reports Is Part Of The Wise Guy Research Consultants Pvt. Ltd. And Offers Premium Progressive Statistical Surveying, Market Research Reports, Analysis & Forecast Data For Industries And Governments Around The Globe.
Contact Us:
Norah
Trent
Ph: +162-825-80070
(Us)
Ph: +44 2035002763 (Uk)
Comments
Post a Comment